Technology evaluation: abatacept, Bristol-Myers Squibb.
Bristol-Myers Squibb is developing the fusion protein abatacept for the potential treatment of various immunological disorders, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. Abatacept is undergoing phase III clinical trials.
Dumont
Francis J
FJ
Medor Consulting, 421 Dogwood Avenue, Egg Harbor Twp, NJ 08234, USA. francisj_dumont@yahoo.com
D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D018122:B7-1 Antigen / Q000276:immunology; D018106:CD28 Antigens / Q000276:immunology; D060908:CTLA-4 Antigen; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008213:Lymphocyte Activation / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007141:Immunoglobulin Fc Fragments; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins